Belimumab, a monoclonal antibody targeting soluble B‐cell activating factor, was used for patients with SLE in our cohort, but they suffered disease progression and did not achieve MMS, and its efficacy in generalized MG is not definite.27 The gene discussed is TNFSF13B; the disease is myasthenia gravis.